ESMO 2023: Advancing Prostate Cancer Care

Rana R. McKay, MD, reviewed the exciting and practice-changing developments in the field of advanced prostate cancer presented at the European Society for Medical Oncology (ESMO) 2023 meeting. Notable highlights included the RADICALS-RT trial, which demonstrated the benefits of early salvage radiation therapy after radical prostatectomy. Other highlights included the presentation by Dr William Kevin Kelly on promising interim results from the AMG 509 phase 1 study showing early efficacy and PSA responses and the ENZA-p study, which revealed enhanced outcomes with combination therapy of enzalutamide and ¹⁷⁷Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Dr McKay concluded by examining the results of the PSMAfore study that presented compelling data supporting the use of ¹⁷⁷Lu-PSMA-617 radioligand therapy before chemotherapy, resulting in improved prostate-specific antigen responses, objective responses, and progression-free survival. Although overall survival benefits weren't seen because of crossover, the findings hold great promise for clinical practice.

Medscape © 2023 WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: ESMO 2023: Advancing Prostate Cancer Care - Medscape - Oct 27, 2023.